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Abstract Cell differentiation is an orderly process that
begins with modiﬁcations in gene expression. This process
is regulated by the acetylation state of histones. Removal of
the acetyl groups of histones by speciﬁc enzymes (histone
deacetylases, HDAC) usually downregulates expression of
genes that can cause cells to differentiate, and pharmaco-
logical inhibitors of these enzymes have been shown to
induce differentiation in several colon cancer cell lines.
Butyrate at high (mM) concentration is both a precursor for
acetyl-CoA and a known HDAC inhibitor that induces cell
differentiation in colon cells. The dual role of butyrate
raises the question whether its effects on HT29 cell dif-
ferentiation are due to butyrate metabolism or to its HDAC
inhibitor activity. To distinguish between these two pos-
sibilities, we used a tracer-based metabolomics approach to
compare the metabolic changes induced by two different
types of HDAC inhibitors (butyrate and the non-metabolic
agent trichostatin A) and those induced by other acetyl-
CoA precursors that do not inhibit HDAC (caprylic and
capric acids). [1,2-
13C2]-D-glucose was used as a tracer and
its redistribution among metabolic intermediates was
measured to estimate the contribution of glycolysis, the
pentose phosphate pathway and the Krebs cycle to the
metabolic proﬁle of HT29 cells under the different treat-
ments. The results demonstrate that both HDAC inhibitors
(trichostatin A and butyrate) induce a common metabolic
proﬁle that is associated with histone deacetylase inhibition
and differentiation of HT29 cells whereas the metabolic
effects of acetyl-CoA precursors are different from those of
butyrate. The experimental ﬁndings support the concept of
crosstalk between metabolic and cell signalling events, and
provide an experimental approach for the rational design of
new combined therapies that exploit the potential syner-
gism between metabolic adaptation and cell differentiation
processes through modiﬁcation of HDAC activity.
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Histone deacetylases (HDAC) belong to a class of enzymes
that remove acetyl groups from lysine residues of histones
and regulate the afﬁnity of protein transcription complexes
for DNA (de Ruijter et al. 2003). Genes that can cause cell
differentiation are normally downregulated by HDAC
activity. However, HDACs are involved in controlling
other living processes, such as signal transduction, cell
growth, the cell cycle and cancer progression (Mariadason
2008; Martin et al. 2007).
Several groups of compounds with different chemical
properties are known HDAC inhibitors (HDI) (Siavoshian
et al. 2000; Villar-Garea and Esteller 2004). These include
short chain fatty acids, hydroxamic acids and benzamides.
Short chain fatty acids (SCFA) are end products of bacte-
rial fermentation in the human large intestine. Butyrate is a
four-carbon SCFA which is a major fuel of colonocytes
(Roediger 1982). In addition to its metabolic effect in
reducing glucose oxidation, it regulates cell proliferation
and induces apoptosis and cell differentiation in several
colon cancer cell lines (Heerdt et al. 1994; Litvak et al.
1998; Marks and Xu 2009). Butyrate has been shown to
activate cyclin D3 and p21, and cause cell-cycle arrest in
the G1 phase (Siavoshian et al. 2000). Moreover, it has
been reported that butyrate affects the genetic proﬁle of
pathways involved in cell growth, apoptosis and oxidative
metabolism (Smith and Workman 2009), and it also has a
direct effect on glucose metabolism. Regarding its meta-
bolic effects, it has been reported that butyrate reduces both
glucose consumption and lactate production while
increasing de novo fatty acid synthesis from butyrate car-
bons and inhibiting ribose synthesis (Boren et al. 2003).
Since these effects have been observed in the mM range of
butyrate concentrations, it has not been possible to dis-
criminate in which extension the metabolic changes
observed are due to butyrate’s HDAC inhibitory effect or
as a consequence of its metabolism. The capacity of
butyrate to induce differentiation has led to the use of this
compound, its derivatives and other HDI in clinical trials
for treating cancers (Perrine et al. 2007; Villar-Garea and
Esteller 2004). Other HDI, like trichostatin A (TSA) and
suberoylanilide hydroxamic acid (SAHA), are non-meta-
bolic compounds acting at nM range and have also been
reported to induce cell differentiation, even though their
effects at metabolic level have not been characterized
(Dangond and Gullans 1998; Munster et al. 2001; Woo
et al. 2007).
In order to distinguish between the metabolic changes
associated with HDI activity and cell differentiation, and
those associated with butyrate effects as metabolic pre-
cursor, we compared the metabolic proﬁle induced by (1)
TSA (acting at nM range), (2) butyrate (acting at mM
range) and (3) caprylic and capric acids (fatty acids pre-
cursors of acetyl-CoA as butyrate but that do not inhibit
HDAC). This metabolic characterization will allow us to
identify the metabolic adaptations associated to butyrate
induced cell differentiation, which can be exploited in a
new combined therapy to enhance cancer cell differentia-
tion or apoptosis.
2 Materials and methods
2.1 Chemicals
All chemicals were purchased from Sigma-Aldrich Co
(St Louis, MO, USA), unless otherwise speciﬁed. Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) and antibiotics
(10,000 U/ml penicillin, 10,000 lg/ml streptomycin) were
obtained from Gibco-BRL (Eggenstein, Germany), foetal
calf serum (FCS) and trypsin-EDTA solution C (0.05%
trypsin-0.02% EDTA) from Invitrogen (Paisley, UK).
Annexin V/FITC kit was purchased from Bender System
(Vienna, Austria), stable [1,2-
13C2]-D-glucose and U-
13C4-
butyrate isotopes were obtained with[99% purity and 99%
isotope enrichment for each position from Isotec Inc.
(Miamisburg, OH). RNase was obtained from Roche
Diagnostics (Mannheim, Germany).
2.2 Cell culture
Human colorectal adenocarcinoma HT29 cells (obtained
from the American Type Culture Collection, HTB-38)
were used in all the experiments. HT29 cells were grown as
a monolayer culture in minimum essential medium
(DMEM with L-glutamine, without glucose and without
sodium pyruvate) in the presence of 10% heat-inactivated
fetal calf serum, 10 mM of D-glucose and 0.1% strepto-
mycin/penicillin in standard culture conditions.
Cell cultures were started with the same cell number
(3 9 10
5), which was achieved by using standard cell
counting techniques. At the end of the experiment, the ﬁnal
cell number were also measured. Seventy-two hours after
seeding, cell medium was removed and fresh supplemented
DMEM was added. TSA or fatty acids (FA) were added to
the cells at their 72 h-IC20 concentrations described in
Sect. 3. Cells were harvested 72 h after treatment. In the
case of GC/MS studies, two separate experiments were
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123performed: (1) to study the effect of different treatments on
glucose metabolism, cells were incubated with [1,2-
13C2]-
D-glucose (50% isotope enrichment) and the corresponding
treatments; and (2) when the metabolism of butyrate itself
was studied, the cultured cells were incubated with unla-
beled glucose but with the 72 h-IC20 of U-
13C4-butyrate
(100% isotope enrichment) and caprylic or capric acid as
indicated.
2.3 Cell proliferation assay
The assay was performed by a variation of the method
described by Mosmann (Mosmann 1983) as speciﬁed in
(Matito et al. 2003). Brieﬂy, 2.5 9 10
3 HT29 cells/well
were cultured in 96 well plates. Concentrations that
inhibited cell growth by 50% (IC50) and 20% (IC20) after
72 h of treatment were calculated based on the survival rate
compared with untreated cells. Relative cell viability was
measured by the absorbance on an ELISA plate reader
(Tecan Sunrise MR20-301, TECAN, Salzburg, Austria) at
550 nm.
2.4 Alkaline phosphatase activity
Alkaline phosphatase activity was measured according to
the published procedures (Bergmeyer 1985). Alkaline
phosphatase (AP) was expressed as nmol of substrate
converted per min and per mg of protein (mU 9 mg
-1).
Protein concentration of cell extracts was determined using
the BCA Protein Assay (Pierce Biotechnology, Rockford,
IL) to calculate the speciﬁc activity of the AP enzyme.
2.5 Cell cycle analysis
The cell cycle was analyzed by using a ﬂuorescence-acti-
vated cell sorter (FACS) at 488 nm in an Epics XL ﬂow
cytometer (Coulter Corporation, Hialeah, FL, USA) as
described elsewhere (Matito et al. 2003). For this assay,
7.5 9 10
4 HT29 cells/well were plated in 6 well plates
with 2 ml of medium. After 72 h, MCFA were added and
the cells were incubated for another 72 h. MCFA doses
used were their respective IC20 and IC50 values. All
experiments were performed ﬁve times with three repli-
cates per experiment.
2.6 Apoptosis assay
Cells were treated as described in Sect. 2.5. After centri-
fugation, cells were washed in binding buffer (10 mM
Hepes pH 7.4, 140 mM sodium chloride, 2.5 mM calcium
chloride) and resuspended in the same buffer. Annexin
V-FITC was added according to the Annexin V-FITC kit.
Following 30 min of incubation at room temperature and in
darkness, propidium iodide (PI) was added 1 min before
FACS analysis at 20 lg 9 ml
-1. Experiments were per-
formed in triplicate. In each experiment, approximately
20 9 10
3 cells were analyzed.
2.7 Glucose and lactate quantiﬁcation
The levels of glucose and lactate in medium were measured
spectrophotometrically. Glucose concentration was mea-
sured using a Cobas Mira chemistry analyzer (Roche
Applied Science). Lactate concentration was measured on
anELISAplatereader(TecanSunriseMR20-301,TECAN).
To measure lactate by GC/MS, this metabolite was
extracted from the cell culture medium by ethyl acetate
after acidiﬁcation with HCl and derivatized to its propy-
lamideheptaﬂuorobutyric form. The m/z 328 (carbons 1–3
of lactate, CI) was monitored for the detection of m0
(unlabeled species), m1 (lactate with one
13C atom,
obtained when recycled through the pentose phosphate
pathway, PPP) and m2 (lactate with two
13C atom, pro-
duced directly by glycolysis) (Lee et al. 1998). Glycolytic
rate was calculated as m2lactate/(m2glucose/2).
2.8 RNA ribose extraction and isotopomer distribution
analysis
RNA ribose was isolated by acid hydrolysis of cellular
RNA after Trizol (Invitrogen) puriﬁcation of cell extracts.
Ribose isolated from RNA was derivatized to its aldonitrile
acetate form using hydroxyl-amine in pyridine and acetic
anhydride. The ion cluster around the m/z 256 (carbons 1–5
of ribose, CI) was monitored (Lee et al. 1998). The oxi-
dative versus nonoxidative ratio was measured as ox/no-
nox = (m1 ? m3)/(m2 ? m3 ? 2 9 m4), since m1 and
m3 need the oxidative branch to be formed, whereas m2,
m3 and m4 species require the nonoxidative branch (twice
in m4).
2.9 Glutamate isolation and isotopomer distribution
analysis
Glutamate was separated from the cell medium using ion-
exchange chromatography (Katz et al. 1989). Glutamate
was converted to its n-triﬂuoroacetyl-n-butyl derivative
and the ion clusters m/z 198 (carbons 2–5 of glutamate, EI)
and m/z 152 (carbons 2–4 of glutamate, EI) were
monitored. Pyruvate dehydrogenase activity relative to
b-oxidation (m2 C4–C5) was calculated by subtracting
m2 of m/z 152 (glutamate fragment C2–C4) from m2 of
m/z 198 (glutamate fragment C2–C5) (Lee 1996).
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1232.10 Gas chromatography/mass spectrometry
Mass spectral data were obtained on a GCMS-QP2010
selective detector connected to a GC-2010 gas chromato-
graph from Shimadzu. The settings were as follows: GC
inlet 250C (200C for lactate measurement), transfer line
280C, MS Quad 150C. A DB-5MS capillary column
(30 m length, 250 lm diameter and 0.25 lm ﬁlm thick-
ness) was used for the analysis of ribose, glutamate, and
lactate.
2.11 Data analysis and statistical methods
In vitro experiments were carried out using three cultures
each time for each treatment and then repeated twice. Mass
spectral analyses were carried out by three independent
automatic injections of 1 ll of each sample by the auto-
matic sampler and were accepted only if the standard
sample deviation was less than 1% of the normalized peak
intensity. Statistical analyses were performed using the
parametric unpaired, two-tailed independent sample t test
with 99% conﬁdence intervals. P\0.01 (*) was consid-
ered to indicate signiﬁcant differences in glucose carbon
metabolism in HT29 cell cultures treated with the different
FA or TSA.
3 Results
3.1 Effect of MCFA and TSA on cell proliferation
Figure 1 shows the effect on cell proliferation of different
fatty acids alone or in combination with butyrate. From
these graphs, an IC20 and an IC50 were obtained for each
individual treatment (butyrate –NaB–, caprylic and capric
acids). The IC20 of caprylic acid (2.25 mM) and NaB
(3 mM) were similar. However, capric acid (0.4 mM)
presented an IC20 that was almost 10-fold lower. An IC50
of 5 mM, 2.75 mM and 0.5 mM were found for NaB,
caprylic and capric treatments, respectively. An IC20 of 180
nM was obtained for the TSA treatment (data not shown).
In combined treatments, a constant dose of 3 mM NaB was
used, while increasing doses of caprylic and capric acid
were added. The graphs show an increase in cell prolifer-
ation when the cells were treated with low concentrations
of caprylic and capric acids. This effect was not observed
in combined treatments of these MCFA with NaB. More-
over, the presence of NaB did not alter signiﬁcantly the
IC20 found for caprylic and capric acids, and an additive
effect was observed after treating the cells with NaB and
caprylic, but not with NaB and capric.
In the following experiments, an IC20 of each compound
was used unless speciﬁed. A concentration of 0.4 mM for
the caprylic treatment was also used in metabolomic
studies, to avoid the dilution effects of caprylic treatments.
When treatments were carried out in combination with
NaB in metabolomic studies, an IC20 of each compound
(NaB and caprylic or capric acids) was used.
3.2 Effect of MCFA on cell cycle and apoptosis
The effects of the different FA on cell cycle and apoptosis
were studied at their respective IC50. The obtained results
(Fig. 2a) showed that not all treatments generated the same
cell cycle proﬁle. NaB and caprylic acid treatment induced
a cell cycle arrest in the G1 phase. However, the effect with
caprylic acid treatment was less pronounced, as the S phase
Fig. 1 Antiproliferative effect of NaB (a), caprylic (b) and capric
acids (c). In combined treatments, a constant dose of 3 mM NaB was
used while increasing doses of caprylic and capric were added.
Results are normalized by the untreated control
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123of the cell cycle was not as affected as it was in the NaB
treatment. The mixed treatments induced a noticeable
arrest in the G1 phase of the cycle, in the same way as the
NaB treatment alone.
All the treatments were associated with a signiﬁcant
increase in apoptosis (Fig. 2b), although necrosis levels did
not increase. In the mixed treatments, the effect of the
different MCFA on apoptosis was more prominent for
caprylic acid, according to the additive effects seen in cell
proliferation.
3.3 Effect of MCFA on cell differentiation
Morphological changes associated with cell differentiation
were evaluated by optical microscopy and the activity of
the alkaline phosphatase (AP) enzyme was also determined
as a marker of cell differentiation. NaB was the only
MCFA agent that induced differentiation; treatment with
the other fatty acids did not produce this effect (Fig. 3). A
slight AP increase was observed in treatments combined
with NaB, due to the presence of butyrate. Cells treated
with TSA showed the characteristic morphology of dif-
ferentiated cells and a very slight increase in AP respect to
the control (data not shown), as described in the literature
(Siavoshian et al. 2000).
3.4 Effect of MCFA and TSA on glucose metabolism
Glucose consumption decreased in both NaB and TSA
treatments, but not in the other fatty acids treatments.
Similarly, lactate production only decreased after NaB
and TSA treatments (Fig. 4a). These results indicate a
reduction in the glycolytic ﬂux in differentiating HT29
cells.
When HT29 cells were incubated with [1,2-
13C2]-D-
glucose, all the treatments reduced the total label incor-
poration into lactate (Fig. 4b). Interestingly, although all
the treatments reduced m1 lactate (data not shown), only
NaB and TSA decreased the direct glycolysis as it is
deduced from the lower glycolytic rate (Fig. 4c).
To ﬁnd the molar enrichment and positional distribution
of
13C labels in ribose, the major isotopomers of ribose
were studied: m1 ribose (formed when [1,2-
13C2]-D-glu-
cose is decarboxylated by the oxidative branch of the PPP)
and m2 ribose (synthesized by the reversible nonoxidative
branch of the cycle). NaB and TSA treatments resulted in a
decrease in the m1 ribose isotopomer (Fig. 5a), which
indicates a decrease in the use of the oxidative branch of
the PPP. Similarly, the oxidative/nonoxidative ratio of PPP
that was estimated according to Ramos-Montoya and col-
leagues (Ramos-Montoya et al. 2006), was also signiﬁ-
cantly lower for NaB and TSA than for the control
(Fig. 5b). This ratio has been reported to increase in tumor
cells vs. normal cells.
Krebs cycle activity was studied by means of glutamate
enrichment and isotopomer distribution analysis. The
pyruvate dehydrogenase (PDH) contribution was markedly
lower in NaB and TSA treatments, slightly lower in the
caprylic treatment and was not affected in the capric
treatment (Fig. 5c). This result suggests that the effect of
Fig. 2 Percentage of cells in a each cell cycle phase and b early/late
apoptosis or necrotic state under the different fatty acid treatments.
The IC50 of each fatty acid was used. Ct: Control; NaB: Butyrate; 1:
Caprylic; 2: Capric. P\0.01 (*) was considered to indicate
signiﬁcant differences in percentages compared to the control
Fig. 3 Alkaline phosphatase activity induced by the different treat-
ments at their IC20 and IC50 doses. An arbitrary value of 1 was
assigned to the controls. Treatments are shown as the value per one
with respect to the control. Ct: Control; NaB: Butyrate; 1: Caprylic; 2:
Capric. P\0.01 (*) was considered to indicate signiﬁcant differ-
ences of the treatments compared to the corresponding control
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123NaB was not due to its metabolization but to the differ-
entiation process, as TSA treatment had the same effect.
3.5 Effect of MCFA on butyrate metabolism
The contribution of butyrate carbons to the Krebs cycle
was assessed, as this compound can be oxidized to obtain
two molecules of acetyl-CoA. For this purpose, HT29 cells
were incubated with U-
13C4-butyrate and the glutamate
isotopomers were determined. The results show that the
different fatty acids combined with NaB did not change
butyrate metabolization (Fig. 6). Only the IC20 of caprylic
acid slightly diluted the label of glutamate from butyrate.
This could be explained by the high amount of carbons
provided by caprylic metabolization, as its concentration
was almost 6 times higher than with capric acid.
4 Discussion
A popular hypothesis of carcinogenesis is the clonogenic
expansion of cancer stem cells, which possess character-
istics of ‘‘undifferentiated’’ cells. Cell differentiation is a
process by which an undifferentiated cell becomes more
specialized and less invasive. The biochemical process that
induces cell differentiation is currently considered as a
viable cancer treatment modality. The differentiation pro-
cess is highly organized and depends on speciﬁc modiﬁ-
cations in gene expression. The acetylation of histones is
one of the most important mechanisms of gene regulation
(Csordas 1990). This modulation is achieved by the action
of histone acetyltransferases (HAT) and HDAC, enzymes
that transfer and remove acetyl groups from histones
respectively. Inhibition of histone deacetylases with HDAC
inhibitors (HDI) to increase histone acetylation and to
induce cell differentiation is potentially an effective ther-
apeutic strategy for cancer treatment. In recent years,
clinical trials with HDI have been performed with prom-
ising results (Kelly et al. 2002; Kouraklis and Theocharis
2006; Oki and Issa 2006; Smith and Workman 2009; Witt
et al. 2009).
Many potent HDIs are modiﬁed hydroxamic acids spe-
cially designed to target histone protein complexes. These
HDIs are effective at nanomolar concentrations because of
their speciﬁcities. On the other hand, butyrate is a well-
known differentiating agent in colon cancer cells (Mari-
adason 2008) that also inhibits cell proliferation and pro-
vokes cell cycle arrest during G1 at millimolar
concentrations. Moreover, a direct effect of butyrate on
inhibition of HDAC activity has been reported (Waldecker
et al. 2008). In this paper we have identiﬁed a common
metabolic ﬂux pattern of cell differentiation induced either
by NaB or TSA that is different from the effect induced by
other MCFA, which neither possess HDI activity nor pro-
voke cell differentiation on HT29 cells. Thus, although
caprylic and capric acids produced a similar degree of cell
cycle arrest and apoptosis to NaB, they did not induce cell
differentiation and had different metabolic changes from
those induced by the two HDI inhibitors tested. These
effects should be applied to other cell lines that do respond
to butyrate treatment, as HCT116 or CaCo-2 (Wilson et al.
2006). The different behavior of capric and caprylic acids
maybeexplainedbythedifferentacyl-CoAdehydrogenases
that metabolize the different length fatty acids (Jethva et al.
2008; Kieweg et al. 1997). However, more experiments
Fig. 4 a Determination of glucose consumption and lactate produc-
tion under the different treatments at their respective IC20. b Total
13C
lactate enrichment from labeled glucose of the different treatments
was calculated as Rmn = m1 ? 2 9 m2 ? 3 9 m3. c Glycolytic rate
expressed as m2lactate/(m2glucose/2). m2glucose represented 48.08% of
total glucose.Ct: Control; NaB: Butyrate; TSA: Trichostatin A; 1:
Caprylic; 1b: Caprylic 0.4 mM; 2: Capric. P\0.01 (*) was
considered to indicate signiﬁcant differences
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123should be conducted in order to test this hypothesis since the
results obtained here neither conﬁrm nor support this point.
HT29 cells treated with butyrate and TSA had a similar
decrease in the glycolytic ﬂux and lactate production due to
a decrease in glucose consumption. On the contrary, cells
treated with caprylic and capric acids showed an increase
in glucose consumption and lactate production. Lactate
enrichment was less than the expected from the obtained
glycolytic ﬂux. Therefore, cells treated with caprylic and
capric acids probably used precursors other than glucose to
produce lactate, such as glutamine (Mazurek and Eigenb-
rodt 2003; Rossignol et al. 2004;V i z a ´ne ta l . 2008). The
decrease in lactate enrichment (Rmn) and in the glycolytic
rate was more prominent after inhibition of histone
deacetylases by NaB and TSA due to the suppression of
tumor glucose uptake and glycolysis. The effect of HDI in
suppressing the high glucose utilization by tumor cells is
supported by the recently published work by Egler and
colleagues (Egler et al. 2008), where synergistic effect of
2-deoxyglucose, an inhibitor of glycolysis and histone
deacetylase inhibitors was observed in combined therapy to
induce glioblastoma cell death. Both NaB and TSA showed
a decrease in the oxidative branch of the PPP (ribose m1),
which could be related to a decrease in ribose synthesis that
was not compensated for by an increase in the nonoxidative
branch. This fact is in accordance with the importance of
the oxidative/nonoxidative ratio in tumor vs. non-tumor
cells, which was previously reported by our group, since an
Fig. 5 RNA ribose isotopomer
distribution of
13C enrichment
under the different treatments,
expressed as % of total ribose
(a). In b, the contribution of
oxidative vs. nonoxidative
branches of PPP was calculated
from the isotopomeric
distribution as ox/
nonox = (m1 ? m3)/
(m2 ? m3 ? 2 9 m4). c
Pyruvate dehydrogenase
contribution under the different
treatments expressed as m2 of
C4–C5 carbons of glutamate
obtained from labeled glucose
(% of total glutamate). Pyruvate
dehydrogenase activity relative
to b-oxidation (m2 C4–C5) was
calculated by subtracting the m2
of m/z 152 (glutamate fragment
C2–C4) from the m2 of m/z 198
(glutamate fragment C2–C5).
Ct: Control; NaB: Butyrate;
TSA: Trichostatin A; 1:
Caprylic; 1b: Caprylic 0.4 mM;
2: Capric. P\0.01 (*) was
considered to indicate
signiﬁcant differences
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123increase in this ratio is related to tumor malignancies
(Ramos-Montoya et al. 2006).
Another difference between HDI inhibitors NaB and
TSA and MCFA caprylic and capric acids was a signiﬁcant
decrease in glucose utilization through PDH (glutamate
m2). Despite similarity between butyrate and caprylic and
capric acids in their metabolism to acetyl-CoA, butyrate
was more effective in reducing PDH activity than the other
MCFAs. However, the effect of butyrate on PDH (gluta-
mate m2) is similar to that of TSA which does not produce
acetyl-CoA. These ﬁndings suggest that the metabolic
pattern observed in cells treated with HDI is due to gene
expression as part of the differentiation program. Accord-
ingly, it has been reported that TSA is able to induce PDK4
gene expression which in turn inhibits PDH activity (Kwon
and Harris 2004;K w o ne ta l . 2006).
To sum up, TSA induces the same metabolic proﬁle
changes as butyrate does. This suggests that the butyrate-
induced HT29 metabolic proﬁle change is the conse-
quence of HT29 differentiation and not the cause of cell
differentiation. The identiﬁcation of the common meta-
bolic proﬁle induced by two different types of HDI
enables the rational design of new combined therapies that
synergize the metabolic adaptation of the cell differenti-
ation process.
5 Concluding remarks
Differentiation causes metabolic changes that are not due
to the use of NaB as an energetic substrate, since other
MCFA did not present the same effects as NaB, but were
observed when cells were incubated in the presence of the
well-know differentiating agent TSA. The metabolic
changes observed with NaB appear to be due to its HDAC
inhibitory activity rather than to its lipid/substrate nature.
We conclude that the observed metabolic changes
accompany the differentiation program that is induced by
the inhibition of histone deacetylation.
The better understanding of the speciﬁc effects of HDI
on tumor cell central metabolic networks reported in this
paper opens new avenues to design combination therapies
with drugs that directly inhibit those pathways that
decrease their ﬂux during the differentiation process to
generate synergies and enhance the effects of HDI.
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